Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 3/20 | 0.71 |
| ▸ | CES1 | P23141 | 3/20 | 0.71 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | SNCA | P37840 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13291390 | 0.83 | CES2 (0.74) | CES2CES1L3MBTL1SNCANPC1 | |
| SCHEMBL8070666 | 0.83 | CES2 (1.00) | CES2CES1L3MBTL1SNCANPC1 | |
| SCHEMBL366061 | 0.81 | CES2 (0.71) | CES2CES1L3MBTL1SNCANPC1 | |
| SCHEMBL7612594 | 0.81 | CES2 (0.71) | CES2CES1L3MBTL1SNCANPC1 | |
| SCHEMBL10703902 | 0.81 | CES2 (0.71) | CES2CES1KEAP1 | |
| SCHEMBL293958 | 0.79 | CES2 (0.68) | CES2CES1L3MBTL1KEAP1HTT | |
| SCHEMBL10701917 | 0.79 | CES2 (0.46) | CES2CES1SNCARAB9AHTT | |
| SCHEMBL12511048 | 0.79 | CES2 (0.68) | CES2CES1L3MBTL1SNCANPC1 | |
| SCHEMBL11570 | 0.79 | CES2 (0.68) | CES2CES1L3MBTL1SNCAHTT | |
| SCHEMBL4962246 | 0.79 | CES2 (0.68) | CES2CES1L3MBTL1SNCANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100357246-C | Preparation of 2,4,6-trichloromethane acid | LUYUAN PHARMACEUTICAL CO LTD (CN) | 2007-12-26 | — | — | CN | disclosed |
| US-7247733-B2 | By halogen exchange reaction using specific guanidinium, phosphonium or sulfonium catalysts, e.g., diethylaminobis[tris(diethylamino)phosphazenyl]-sulfonium bromide, diethylaminobis(tetramethyl-guanidino)sulfonium bromide and (N,N-dimethylimidazolidino)tetramethyl-guanidinium chloride | LANXESS DEUTSCHLAND GMBH (DE) | 2007-07-24 | — | — | US | disclosed |
| EP-1266904-B1 | Improved process for preparing fluorinated aromatic compounds | SALTIGO GMBH (DE) | 2006-09-13 | — | — | EP | disclosed |
| US-7091362-B2 | Heating aromatic compound substituted with halogen that is exchangeable for fluorine with fluoride and compound such as Diethylaminobis(tetramethylguanidino)sulfonium bromide to produce fluorinated aromatics | BAYER AKTIENGESELLSCHAFT (DE) | 2006-08-15 | — | — | US | disclosed |
| CN-1746147-A | Preparation of 2,4,6-trichloromethane acid | LUYUAN PHARMACEUTICAL CO LTD D (CN) | 2006-03-15 | — | — | CN | disclosed |
| US-20050228201-A1 | By halogen exchange reaction using specific guanidinium, phosphonium or sulfonium catalysts, e.g., diethylaminobis[tris(diethylamino)phosphazenyl]-sulfonium bromide, diethylaminobis(tetramethyl-guanidino)sulfonium bromide and (N,N-dimethylimidazolidino)tetramethyl-guanidinium chloride | HENRICH MARIELOUISE | 2005-10-13 | — | — | US | disclosed |
| US-20030036667-A1 | Heating aromatic compound substituted with halogen that is exchangeable for fluorine with fluoride and compound such as Diethylaminobis(tetramethylguanidino)sulfonium bromide to produce fluorinated aromatics | LANXESS DEUTSCHLAND GMBH (DE) | 2003-02-20 | — | — | US | disclosed |
| EP-1266904-A1 | Improved process for preparing fluorinated aromatic compounds | BAYER AG (DE) | 2002-12-18 | — | — | EP | disclosed |
| EP-0693466-B1 | Process for the preparation of aromatic fluorinated compounds and diamides | BAYER AG (DE) | 2001-10-17 | — | — | EP | disclosed |
| US-5672765-A | Process for the preparation of aromatic fluorinated compounds and novel diamides | BAYER AKTIENGESELLSCHAFT (DE) | 1997-09-30 | — | — | US | disclosed |
| EP-0693466-A1 | Process for the preparation of aromatic fluorinated compounds and diamides | BAYER AG (DE) | 1996-01-24 | — | — | EP | disclosed |
| US-5457104-A | Antibacterials | BAYER AKTIENGESELLSCHAFT (DE) | 1995-10-10 | — | — | US | disclosed |
| EP-0270964-B1 | PROCESS FOR OBTAINING SUBSTITUTED FLUOROBENZENES | BAYER AG (DE) | 1992-07-08 | — | — | EP | disclosed |
| US-4868347-A | SOLVENT EXTRACTION | BAYER AKTIENGESELLSCHAFT (DE) | 1989-09-19 | — | — | US | disclosed |
| US-4847442-A | Process for the preparation of difluorobenzenes | ALLIED-SIGNAL INC. (US) | 1989-07-11 | — | — | US | disclosed |
| EP-0293747-A2 | Process for the preparation of fluoride-substituted carboxylic-acid chlorides | BASF Aktiengesellschaft (DE) | 1988-12-07 | — | — | EP | disclosed |
| US-4420433-A | REACTION WITH SILICON TETRACHLORIDE OR TITANIUM TETRACHLORIDE | BAYER AKTIENGESELLSCHAFT (DE) | 1983-12-13 | — | — | US | disclosed |
| EP-0071065-A1 | Process for the preparation of fluorine-substituted carboxylic-acid chlorides and aldehydes | BAYER AG (DE) | 1983-02-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030036667-A1 | Heating aromatic compound substituted with halogen that is exchangeable for fluorine with fluoride and compound such as Diethylaminobis(tetramethylguanidino)sulfonium bromide to produce fluorinated aromatics | AFF1, FLI1, AFF2 | CES2 2677/4885CES1 3272/4885L3MBTL1 3582/4885 |
| US-20050228201-A1 | By halogen exchange reaction using specific guanidinium, phosphonium or sulfonium catalysts, e.g., diethylaminobis[tris(diethylamino)phosphazenyl]-sulfonium bromide, diethylaminobis(tetramethyl-guanidino)sulfonium bromide and (N,N-dimethylimidazolidino)tetramethyl-guanidinium chloride | PFAS, GDI2, EWSR1 | CES2 830/4885CES1 2641/4885L3MBTL1 3167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.